Loss widens sharply. Dianthus Therapeutics, Inc. (DNTH) reported a loss of $1.43 per share for Q4 2025, wider than the expected loss of $1.03 per share. The biotech posted a net loss of $64.4 million for the quarter. The wider-than-expected loss marks a significant deterioration from the prior quarter’s $0.97 per share loss and $0.81 per share loss reported in Q4 2024.
Revenue collapses year-over-year. The company generated just $280,000 in revenue for the quarter, down 78.9% from $1.3 million in the year-ago period. Sequentially, revenue declined from Q3 2025’s $396,000. The minimal revenue base reflects the company’s early-stage development profile, with the business still heavily dependent on research milestones rather than commercial product sales. Despite the operational losses, shares surged 21.5% on volume of 4.6 million shares, suggesting investors are focused on pipeline developments rather than near-term profitability.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.